a month ago
APLS
AnalystsEliana MerleEliana Merle's Stock Forecasts
AnalystsEliana Merle
Sectors:
Industries:
Analyst Ranking
Top 20%
#870 out of 4337 analysts
Average Return
+7.45%
Win Rate
41%13 out of 32
Risk vs Reward
Poor
Good
Eliana Merle's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +237.97% | $11.01 | $37.21 | 2022-08-01 - 2023-05-03 | Strong Buy |
Cymabay Therapeutics IncCBAY | +213.84% | $1.59 | $4.99 | 2020-03-12 - 2021-03-12 | Strong Buy |
Kadmon Holdings IncKDMN | +148.04% | $3.83 | $9.50 | 2021-05-20 - 2021-11-09 | Strong Buy |
Amicus Therapeutics IncFOLD | +104.46% | $9.87 | $20.18 | 2020-02-03 - 2021-02-04 | Strong Buy |
Tesaro IncTSRO | +103.03% | $36.92 | $74.96 | 2018-10-21 - 2019-01-18 | Strong Buy |
Eliana Merle Analyst Color
Get additional color on Eliana Merle's coverage of popular stocks
2 years ago
MRNA
Eliana Merle's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
89bio IncETNB | 1 | Strong Buy | $36.00 | +136.38% | Initiates Coverage On | a month ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $83.00 | +82.98% | Initiates Coverage On | a month ago |
Apellis Pharmaceuticals IncAPLS | 3 | Strong Buy | $64.00 | +48.56% | Maintains | a month ago |
Cymabay Therapeutics IncCBAY | 3 | Strong Buy | $18.00 | +25.70% | Initiates Coverage On | a month ago |
Kodiak Sciences IncKOD | 1 | Hold | $4.00 | +96.08% | Downgrades | 2 months ago |
Moderna IncMRNA | 2 | Strong Buy | $191.00 | +94.56% | Upgrades | 3 months ago |
Uniqure NvQURE | 4 | Strong Buy | $42.00 | +513.14% | Maintains | 4 months ago |
Iveric Bio IncISEE | 2 | Hold | $40.00 | +0.13% | Downgrades | 5 months ago |
Biontech SeBNTX | 2 | Hold | $153.00 | +48.37% | Maintains | 6 months ago |
Terns Pharmaceuticals IncTERN | 1 | Strong Buy | $19.00 | +270.37% | Initiates Coverage On | 8 months ago |
Curevac NvCVAC | 1 | Strong Buy | $18.00 | +142.59% | Upgrades | 8 months ago |
Madrigal Pharmaceuticals IncMDGL | 1 | Strong Buy | $337.00 | +123.27% | Maintains | 9 months ago |
Gossamer Bio IncGOSS | 2 | Strong Buy | $8.00 | +928.28% | Maintains | 10 months ago |
Monte Rosa Therapeutics IncGLUE | 1 | Strong Buy | $22.00 | +262.44% | Initiates Coverage On | a year ago |
Regenxbio IncRGNX | 1 | Strong Buy | $47.00 | N/A | Maintains | a year ago |
Kadmon Holdings IncKDMN | 1 | Strong Buy | $9.00 | N/A | Initiates Coverage On | 2 years ago |
Amicus Therapeutics IncFOLD | 2 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 2 years ago |
Kymera Therapeutics IncKYMR | 1 | Strong Buy | $80.00 | N/A | Initiates Coverage On | 2 years ago |
Zentalis Pharmaceuticals IncZNTL | 2 | Strong Buy | $91.00 | N/A | Initiates Coverage On | 2 years ago |
Anaptysbio IncANAB | 2 | Hold | $29.00 | N/A | Initiates Coverage On | 2 years ago |
Arvinas IncARVN | 2 | Strong Buy | $123.00 | N/A | Initiates Coverage On | 2 years ago |
Bridgebio Pharma IncBBIO | 1 | Strong Buy | $80.00 | N/A | Initiates Coverage On | 2 years ago |
Galapagos NvGLPG | 2 | Hold | $134.00 | N/A | Maintains | 3 years ago |
Alexion Pharmaceuticals IncALXN | 1 | Hold | $121.00 | N/A | Initiates Coverage On | 3 years ago |
Selecta Biosciences IncSELB | 1 | Strong Buy | $10.00 | N/A | Initiates Coverage On | 4 years ago |
Tesaro IncTSRO | 1 | Strong Buy | $68.00 | N/A | Maintains | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.